Aggarwal, Bhumika
Al-Moamary, Mohamed
Allehebi, Riyad
Alzaabi, Ashraf
Al-Ahmad, Mona
Amin, Muhammad
Damayanti, Triya
Van Tho, Nguyen
Quyen, Pham Thi Le
Sriprasart, Thitiwat
Poachanukoon, Orapan
Yu-Lin, Andrea Ban
Ismail, Ahmad Izuanuddin
Limpin, Maria Encarnita B.
Koenig, Steven
Levy, Gur
Phansalkar, Abhay
Rafih, Farouz
Silvey, Mark
Miriams, Laura
Milligan, Gary
Funding for this research was provided by:
GSK Pharmaceuticals
Article History
Received: 15 April 2024
Accepted: 13 May 2024
First Online: 14 June 2024
Declarations
:
: Andrea Ban Yu-Lin received consulting fees from GSK, AstraZeneca, Boehringer Ingelheim, Menarini, Orient Pharma, and Pfizer and received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GSK, AstraZeneca, Boehringer Ingelheim, Orient Pharma, Bayer, and Pfizer. Abhay Phansalkar is an employee of GSK and holds stocks/shares in GSK. Ashraf Alzaabi, Ahmad Izuanuddin Ismail, Orapan Poachanukoon, Muhammad Amin, and Thitiwat Sriprasart declared no competing interests. Bhumika Aggarwal and Gur Levy are employees of GSK and received support from GSK for the current manuscript. Farouz Rafih is an employee of GSK and does not hold stocks/shares in GSK. Gary Milligan, Laura Miriams, and Mark Silvey are employees of Adelphi Real World, which received funding to conduct the study and medical writing support for this manuscript. Mona Al-Ahmad received grants or contracts from Kuwait University and honoraria for lectures and advisory boards from GSK, AstraZeneca, and Sanofi. Mohamed Al-Moamary received consulting fees from Alhekma; received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GSK, Novartis, AstraZeneca, and Abbott; and participated in a Data Safety Monitoring Board or Advisory Board for GSK. Maria Encarnita B. Limpin received honoraria for lectures on asthma from GSK, lectures on VTE from Corbridge, and lectures on COPD from Inova; she has been the past President of the Philippine College of Physicians & Philippine College of Chest Physicians, and Executive Director of Action on Smoking & Health, Philippines. Nguyen Van Tho received honoraria for lectures from GSK, AstraZeneca, Boehringer Ingelheim, and Novartis and received support for attending meetings from GSK, AstraZeneca, and Boehringer Ingelheim. Pham Thi Le Quyen received honoraria for lectures, presentations from GSK, AstraZeneca, Boehringer Ingelheim, Novartis, and Abbott. Riyad Allehebi received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GSK, AstraZeneca, and Sanofi and received support from AstraZeneca, GSK, and Sanofi for attending meetings and/or travel. Steven Koenig received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GSK. Triya Damayanti received payment or honoraria for lectures, presentations, speaker bureaus from GSK, AstraZeneca, Wellesta, and Zuelig and received support for attending meetings and/or travel from Zambon and GSK.
: Patients and physicians in all countries were sampled and recruited through high-quality panel providers certified by the International Organization for Standardization (ISO 20252:2019 Market, Opinion and Social Research, including Insights and Data Analytics — Vocabulary and Service Requirements; ISO 27001 Information Security Management) and fully compliant with country-specific regulations (e.g. General Data Protection Regulation, The British Healthcare Business Intelligence Association [BHBIA] Adverse Event Reporting, and European Union [EU] Safe Harbor) for collecting patient and physician data. Before commencing the study, the Western Copernicus Group Institutional Review Board (WCG IRB; WCG Clinical, Inc; Princeton, USA; registration identifier IRB00000533) reviewed and approved the protocol, informed consent forms, and other relevant documents (such as advertisements). The IRB certified that the project protocol ensured respondent confidentiality and privacy, aligning with Adelphi Real World company policies. Additionally, the IRB determined that the research qualified for a waiver of documentation of consent according to 45 CFR 46.117(c)(1)(ii) [2018 Requirements] and 45 CFR 46.117(c)(2) [Pre-2018 Requirements]. IRB details for this study include reference number 1360929 and tracking number 20234154. Prior to participation, respondents provided informed consent, including consent for the publication of findings. The study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki.